UTRECHT, THE NETHERLANDS — Neuromod Devices, a medical technology company focused on tinnitus treatment technology, has partnered with HearConsult to make the Lenire tinnitus treatment device available in The Netherlands.
Lenire® is a bimodal neuromodulation device that has been shown to provide clinically significant relief from tinnitus across multiple clinical trials and in real-world patient settings.1,2,5
Tinnitus, commonly described as ringing, hissing, or buzzing in the ears, affects more than 2 million adults in The Netherlands.3 A recently published paper reported that tinnitus incidence in The Netherlands increased by 33% between 2012 and 2021,4 attributing the rise to loud music exposure, noise pollution, and changing listening habits. The largest increase was seen in younger adults between 20 and 44 years old.
“There has been a significant increase of people whose primary concern is tinnitus in our clinic and this is common across all Dutch audiology practices. We have seen the remarkable evidence from clinics across Europe and the United States and we are excited to make this proven treatment option available at our clinic.”
–Koen Vernooij Au.D., owner of HearConsult
Lenire Now Available Across Europe and the USA
The Netherlands is the latest country to make Lenire® available, following launches in Denmark, Norway, Spain, Italy, Poland, Sweden, Switzerland, and further expansion in the UK.
Utrecht-based researcher Jan van Dam described his experience living with tinnitus for decades and traveling to Belgium for treatment with Lenire before the device became available in The Netherlands:
“As a researcher, I spend quite a lot of time focusing in quiet spaces, and the noise from my tinnitus was very distracting, and it also made socialising difficult. I found Lenire’s clinical research compelling and now, after treating my tinnitus with the device, the tinnitus is much quieter, and it no longer annoys me.”
–Jan van Dam
Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to be effective in clinical trials and in real-world patient analyses. Lenire’s bimodal neuromodulation combines tongue and auditory stimulation to drive long-term changes in the brain that have been shown to reduce tinnitus severity.
In 2023, Lenire became the first and only bimodal neuromodulation device to receive De Novo approval from the U.S. Food and Drug Administration (FDA).
That De Novo approval was based on the success of Lenire’s TENT-A3 controlled clinical trial. TENT-A3 found that Lenire was clinically superior to sound therapy, which served as the trial’s control treatment.5
Nature – Scientific Reports published results from Lenire’s second large-scale clinical trial, TENT-A2. TENT-A2 showed that 95% of compliant patients reported tinnitus improvement, while 91% reported long-term relief that sustained for at least one year after treatment ended.1
Nature Communications Medicine recently published results from 220 tinnitus patients treated with Lenire in a real-world clinical setting at Alaska Hearing & Tinnitus Center. In that analysis, 91.5% of patients reported clinically meaningful reductions in tinnitus after treatment with Lenire.2
Lenire is available in The Netherlands through HearConsult following a suitability assessment.
Tinnitus Information Sessions in Mijdrecht
HearConsult is running four information sessions for tinnitus patients on March 26 and 27 in Mijdrecht. There will be two sessions per day at 14:00 and 20:00. The sessions will cover the causes of tinnitus, available treatment options, and tips for managing tinnitus.
Attendance is free, but places are limited and must be reserved in advance at https://www.hearconsult.nl/. Complimentary parking and refreshments provided.
About Neuromod Devices
Neuromod Devices is a global medical technology company with offices in Ireland and the USA. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.
Neuromod has completed extensive clinical trials to confirm the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, to treat this common but underserved disorder.
For more information about Neuromod visit www.neuromod.com.
About Lenire
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in large-scale clinical trials.
Bimodal neuromodulation is the stimulation of nerves with two paired stimuli for therapeutic purposes. The tinnitus treatment device that was used in the study, known as Lenire, was developed by Neuromod Devices. It consists of wireless (Bluetooth ®) headphones that deliver sequences of audio tones to both ears, combined with electrical stimulation pulses delivered to the surface of the tongue via 32 electrodes on a proprietary device trademarked as Tonguetip®. The device’s settings can be configured to provide treatment with different combinations of audio and electrical stimuli.
The timing, intensity and delivery of the stimuli are controlled by an easy-to-use handheld controller that each participant is trained to use prior to continuing treatment from home. Patients with tinnitus are prescribed Lenire by an appropriately qualified healthcare professional, such as an Audiologist or ENT Surgeon, after an assessment for suitability and can complete treatment from home in between follow-up appointments with their clinician.
About HearConsult
HearConsult is a specialty tinnitus care clinic with locations in Mijdrecht and Utrecht. Founded by Koen Vernooij, AuD, a practitioner with over 30 years of experience in the hearing care sector, HearConsult focuses on personalised care, honesty, and education for tinnitus patients.
About Tinnitus
Tinnitus, which is commonly known as ‘ringing in the ears’, is a complex neurological condition that causes a perception of sound when there is no external source. It is estimated that at least 2 million people in The Netherlands are currently living with tinnitus.4
References
1 Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, nature.com/articles/s41598-022-13875-x (2022)
2 Mc Mahan, E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment, Commun Med (2025)
3 R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021)
4 Bes, J. et al, The impact of tinnitus on Dutch GPs: A retrospective study using routine healthcare data, https://doi.org/10.1371/journal.pone.0313630 (2024)
5 Boedts, M., Beuchner, A., Khoo, S.G. et al Combining sound with tongue stimulation for the treatment of tinnitus. A multi-site single-arm controlled pivotal trial. Nature Comms. (2024)
Source: Neuromod
